Pryte Pharmaceuticals isopropyl tobly bromide inhalation aerosol imitation class 4 listing application was accepted

Medicine Network December 21st, recently, CDE official website shows that four Trump Reiter Pharmaceuticals isopropyl tobly bromide inhalation aerosols to mimic category 4 listing applications were accepted.
meters of intranet data show that in 2019, China's public medical institutions terminal isopropyl bromide inhaler sales exceeded 1 billion yuan, the first half of this year affected by the outbreak, down more than 30% yoY.
, Grigg Ingham has a market share of more than 90 per cent.
Sales of isopropyl bromide inhalants in China's public medical institutions in recent years (units: 100 million yuan) Source: China's public medical institutions terminal competition pattern isopropyl tobly bromide inhalation aerosols treatment category belongs to anti-asthma drugs. according to
meters of intranet data, in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (China's public medical institutions) terminal isopropyl bromide inhaler sales exceeded 1 billion for the first time;
brand structure, Grigg Ingham has the largest market share, accounting for more than 90%.
so far, isopropyl tobly bromide inhalation aerosols have not been evaluated by enterprises.
this time, four Trump Reiter Pharmaceuticals isopropyl tobly bromide inhalation aerosols to mimic category 4 to submit a listing application, approved will be treated as a review.
recently, the inhalation solution of sulphate saldenamide alcohol for inhalation by the Four Trumps Pharmaceuticals was approved for production in a generic category 4 and was evaluated as such.
2019, China's public medical institutions terminal salbitamine inhaler sales of more than 1 billion yuan.
。